Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens

Alessio Grimaldi1,14, Ilenia Cammarata1,14, Carmela Martire1, Chiara Focaccetti1, Silvia Piconese1, Marta Buccilli1, Carmine Mancone2, Federica Buzzacchino3, Julio Rodrigo Giron Berrios3, Nicoletta D’Alessandris4, Silverio Tomao3, Felice Giangaspero4,5, Marino Paroli6, Rosalba Caccavale6, Gian Paolo Spinelli7, Gabriella Girelli2, Giovanna Peruzzi8, Paola Nisticò9, Sheila Spada9, Mariangela Panetta9, Fabiana Letizia Cecere10, Paolo Visca11, Francesco Facciolo12, Flavia Longo3 & Vincenzo Barnaba1,8,13✉

Here, we developed an unbiased, functional target-discovery platform to identify immunogenic proteins from primary non-small cell lung cancer (NSCLC) cells that had been induced to apoptosis by cisplatin (CDDP) treatment in vitro, as compared with their live counterparts. Among the multitude of proteins identified, some of them were represented as fragmented proteins in apoptotic tumor cells, and acted as non-mutated neoantigens (NM-neoAgs). Indeed, only the fragmented proteins elicited effective multi-specific CD4+ and CD8+ T cell responses, upon a chemotherapy protocol including CDDP. Importantly, these responses further increased upon anti-PD-1 therapy, and correlated with patients’ survival and decreased PD-1 expression. Cross-presentation assays showed that NM-neoAgs were unveiled in apoptotic tumor cells as the result of caspase-dependent proteolytic activity of cellular proteins. Our study demonstrates that apoptotic tumor cells generate a repertoire of immunogenic NM-neoAgs that could be potentially used for developing effective T cell-based immunotherapy across multiple cancer patients.

1 Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, 00161 Rome, Italy. 2 Dipartimento di Medicina Molecolare, Sapienza Università di Roma, 00161 Rome, Italy. 3 Dipartimento di Scienze Radiologiche, Oncologiche e Anatomo Patologiche, Oncologia Medica, Università di Roma, 00161 Rome, Italy. 4 Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy. 5 IRCCS Neuromed, Pozzilli, Isernia, Italy. 6 Dipartimento di Scienze e Biotecnologie Medico-Chirurgiche, Sapienza Università di Roma - Polo Pontino, 04100 Latina, Italy. 7 UOC Oncologia Universitaria, ASL Latina (distretto Aprilia), Sapienza Università di Roma, Via Giustiniano snc, 04011 Aprilia, Latina, Italy. 8 Center for Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, 00161 Rome, Italy. 9 Tumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. 10 Medical Oncology 1, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. 11 Unit of Pathology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. 12 Thoracic Surgery Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. 13 Istituto Pasteur - Fondazione Cenci Bolognetti, 00185 Rome, Italy. 14These authors contributed equally: Alessio Grimaldi, Ilenia Cammarata. ✉Email: vincenzo.barnaba@uniroma1.it
lung cancer is the major cause of cancer-related death worldwide, and non-small-cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, of which lung ade
nocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most common subtypes. Additionally, NSCLC is mole
cularly heterogeneous, because of the amazing diversity of somatic genome mutations, including mutations of genes con
tributing to carcinogenesis (driver genes; e.g., KRAS, EGFR, TP53, etc.), and passenger mutations of genes unrelated to tumor growth, a large part of which are patient specific (private) and confers a huge antigenic heterogeneity to various tumors including NSCLC.

In the past decade, immunotherapy has achieved extraordinary objective response rates for the treatment of tumors, particularly by using monoclonal antibodies (mAbs) specific to various inhibi
tory signaling molecules (immune checkpoints, such as programmed death-1 [PD-1] or cytotoxic T-lymphocyte antigen-4 [CTLA-4]) that are strongly upregulated by exhausted tumor-associated T cells (e.g., anti-CTLA-4 and/or anti-PD-1 mAbs) have not been shown to be efficient for all tumor types and may cause a partial remission in the majority of tumors. Innovative immunotherapy strategies are in progress, particularly based on the combination of different approaches, including new and current inhibitors providing immune check
point blockade (ICB), as well as tumor vaccines against neoantigens (neoAgs) that are generated as a consequence of the wide tumor genome mutations. T cells specific to either public or private neoAgs, which are encoded by somatic genome mutations, are not purged by central tolerance, can migrate in the periphery, and be of particular relevance to tumor control. This conclusion is supported by the association between tumor T cell infiltration and mutational load, or between the expansion of mutated neoAg-specific T cells and the reinvigoration of anti-tumor T cell immunity following ICB. However, despite the high mutational burden and the huge tumor T cell infiltration in several tumors including NSCLC, the frequencies of the related neoAg-specific T cells are relatively very low. In the light of these evidences, it is possible that a consistent proportion of tumor-associated T cells may be specific to non-mutated (NM)-neoAgs generated by various forms of protein modifications occurring at post-transcriptional level, such as protein splicing, dysregulated phosphorylation or glycosylation, proteasome generation of spliced peptides, peptide citrullination, impaired peptide processing in TAP-deficient tumor cells, or proteasomal degradation of defective ribosomal products (DRIPS). These NM-neoAgs may provide rational targets for cancer immu
notation, because they should not be expressed or expressed at concentrations that are not enough to delete specific T cells in the thymus. Potentially, also chemotherapy or radiotherapy may generate immunogenic NM-neoAgs in dying tumor cells, through their capacity to induce immunogenic cell death (ICD). These cells may be used as the endogenous vaccine and boosts the ICB effects. However, despite the large body of evidences on how ICD occurs, few evidences have been reported about the nature of antigens becoming immunogenic upon ICD.

Here, we used stable isotope labeling by amino acids in cell culture (SILAC)-based mass spectrometry (MS) to quantitatively compare the proteome of primary NSCLC cells that had been made apoptotic by cisplatin (CDDP) treatment in vitro and their live counterparts. The expression of a multitude of proteins was found differently regulated, some of which were represented as fragmented proteins in CDDP-treated apoptotic (CDDP-ap) tumor cells, as the result of a caspase-dependent proteolytic activity. Then, we interrogated memory T cells from NSCLC patients, to detect whether these fragmented proteins were generated in tumor cells following chemotherapy-induced apoptosis, and whether they could act as immunogenic NM-neoAgs capable of inducing potentially protective anti-tumor immune responses. 

Results

Identification of proteome changes in apoptotic NSCLC cells.

SILAC-based MS was used to identify changes in the proteome of primary NSCLC cells, as previously described (Fig. 1). In brief, primary NSCLC cells (named EpT1Lu line, isolated from a sur
gery specimen obtained and characterized, as described in Methods section) were metabolically labeled with heavy (\(^{13}\text{C}_6\)-Lys and \(^{13}\text{C}_6\)-\(^{15}\text{N}_4\)-Arg) and light (\(^{12}\text{C}_6\)-Lys and \(^{12}\text{C}_6\)-\(^{14}\text{N}_4\)-Arg) isotope medium, and subsequently induced to apoptosis by 0.625 \(\mu\)M CDDP treatment (72 h) (Fig. 1a). Apoptosis was validated by the consistent upregulation of Annexin V and activated caspase-3 in CDDP-treated cells (Supplementary Fig. 1). Non-labeled EpT1Lu cells were grown in light medium (\(^{12}\text{C}_6\)-Lys and \(^{12}\text{C}_6\)-\(^{14}\text{N}_4\)-Arg) and maintained in viable condition. Then, apoptotic cells and live cells were sorted from heavy and light NSCLC populations, respectively (Fig. 1a). A reverse SILAC experiment (SILAC reverse), switching heavy and light media, was also performed. Apoptotic (heavy) and live (light) cells obtained in five independent experiments were pooled and lysed, and equal amounts of proteins from each cell line were mixed (Fig. 1a). One hundred micrograms of this sample was separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and the gel lane was cut into 16 sections ranging from 5 to 250 kDa (Fig. 1b). Proteins from each gel section were digested and quantified using liquid chromatography (nanoLC) followed by MALDI-TOF/TOF (matrix-assisted laser desorption/ionization tandem time-of-flight) analysis. By this procedure, among the 815 proteins differently expressed between apoptotic (heavy) and live (light) NSCLC cells, some of them resulted as fragmented proteins upregulated in apoptotic NSCLC cells (Fig. 1b). To select fragmented proteins originated by CDDP-dependent apoptosis, we used the electrophoresis-derived molecular weight (MWexp) of the protein as the identification constraint. Fragmented proteins were identified on the basis of the evidence that the MWexp of a polypeptide resulted lower than the theoretical molecular weight (MWcal) of the corresponding entire protein (Fig. 1b and Table 1). Comparison between apoptotic (heavy) and live (light) NSCLC cells in forward SILAC experiments showed that out of a total of 815 proteins identified and quantified (Supplementary Data 1 reported in Description of additional supplementary items), 253 proteins (31%) were found overabundant, 439 (54%) proteins were found downregulated, whereas 16 (2%) resulted fragmented proteins upregulated in apoptotic cells (Fig. 1c). Notably, similar results were found in the reverse SILAC, thus showing that a large number of proteins were differentially expressed between apoptotic and live NSCLC cells in forward and reverse SILAC experiments.

In conclusion, we identified a number of non-mutated tumor neoAgs that are upregulated in apoptotic NSCLC cells and that may act as immunogenic NM-neoAgs capable of inducing potentially protective anti-tumor immune responses.
highlighting a high reproducibility between the SILAC replicates (Supplementary Fig. 2a; Supplementary Data 1). Accordingly, 16 and 11 identifications resulting as fragmented proteins in forward and reverse SILAC experiments, respectively, were found upregulated in apoptotic cells (Table 1; the nature and function of these proteins are described in Supplementary Notes reported in Supplementary Informations). Among them, six fragments were identified in both SILAC experiments (Table 1). Biological process-based gene ontology (GO) analysis (PANTHER [Protein ANalysis THrough Evolutionary Relationships], version 14.1) of upregulated proteins confirmed gene enrichment categories in the frame of execution phase of apoptosis and apoptotic signaling pathway (Supplementary Fig. 2b).

To validate the relationship between proteins identified by SILAC-based proteomics and NSCLC, immunohistochemical (IHC) analyses were performed in cancer tissues derived from various patients, by using (commercially) available specific mAbs that were obtained by immunization with the proactivator polypeptide (PSAP)_{325-524}, or the N terminal domain of LYRIC sequences. Both these sequences contained the peptides that were associated with the related proteins with a confidence of more than 95% by spectra analyses (Table 1; Supplementary Data 1). These mAbs detected the related antigenic proteins in both live and apoptotic NSCLC cells in tumor tissues derived from five independent patients tested, who were submitted to the surgery resection upon neo-adjuvant chemotherapy (Supplementary Fig. 3), but not in tumor tissues from two patients, who were submitted to the surgery resection without neo-adjuvant chemotherapy. These data suggest that proteins identified in freshly isolated NSCLC cells by SILAC-based proteomics are represented in NSCLC tissue from various patients after chemotherapy. As expected, anti-PSAP and anti-LYRIC antibodies detected the related proteins considerably more in live than in apoptotic tumor cells by IHC analysis (Supplementary Fig. 3).
Fig. 3), in agreement with the rule that antibodies generally recognize the native (folded) proteins rather than the corresponding fragmented (unfolded) forms that, vice versa, are more efficiently processed and presented to T cells by antigen-presenting cells (APCs)31, such as those we found upregulated in apoptotic tumor cells by SILAC-based proteomics.

**T effector cell responses to multiple NM-neoAg peptides.** To assess the functional relevance of SILAC findings, we compared the immunogenicity of proteins resulted fragmented or not in CDDP-ap or live NSCLC cell line (EpT11Lu). In particular, we analyzed longitudinal memory T cell responses in peripheral blood mononuclear cells (PBMCs) isolated from 14 NSCLC (10 LUAD and 4 LUSC) patients, as compared with healthy donors (HDs), by flow cytometry (FC) (Table 2). All patients showed a stage IV NSCLC, and four of them had previously experienced a surgical treatment, without any neo-adjuvant therapy. All patients were studied before (time 0 [T0]) and after a treatment with various cycles of a chemotherapy protocol (including CDDP) (T1), whereas 12 of them were also studied after a subsequent treatment with several cycles of anti-PD-1 mAb (nivolumab) (T2) (Table 2). As a control, we also studied T cell responses in PBMCs from seven patients with earlier NSCLC stage (4 with IIIA, 1 with IIIB, 1 with IIA and 1 with IA), who did not require neo-adjuvant chemotherapy, and whose blood sample was obtained immediately before (1 day) the surgery resection (naive patients) (Supplementary Table 1). The effector (eff) responses were evaluated by calculating the percentage of CD8+ or CD4+ T cells prominently producing interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), or both ex vivo (i.e., without a previous stimulation in vitro), in response to a peptide matrix composed of 12 peptide pools. Each of these peptide pools contained 6–7 synthetic 20-mer peptides (overlapping of 12 residues), spanning eight randomly selected proteins that were found overrepresented in the form of fragmented proteins in CDDP-ap NSCLC cells, as compared with live NSCLC cells using SILAC-based MS analysis (i.e., olfactory receptor 5H2; Ras and EF-hand domain-containing protein; proactivator polypeptide; protein A (VAPA); protein A (VAPA); protein A (VAPA); protein A (VAPA). Supporting that these responses can be defined as effector memory, the majority of both CD8+ and CD4+ T eff cells specific to the peptide pools derived from the fragmented proteins (i.e., NM-neoAgs) were confined within the eff memory CCR7+CD45RA- (EM) or the CCR7+CD45RA- (EMRA) cell subsets, rather than the naive CCR7+CD45RA- (N) or the central memory CCR7+CD45RA- (CM) subsets, and were higher in patients than in HDs, both at T1 (after the chemotherapy protocol including CDDP) and more at T2 (after the consecutive treatment with nivolumab), but not at T0 (Figs. 2 and 3). Furthermore, the majority of responses were higher at both T1 and T2 than at T0, as well as at T2 as compared with T1, whereas the remaining

---

**Table 1 List of fragmented proteins upregulated by CDDP-treated NSCLC cells in forward and reverse SILAC experiments.**

| Accession number | Protein name (gene name) | Peptides | Late apoptotic/live ratio | MWcal (kDa) | MWexp range (kDa) |
|------------------|--------------------------|----------|--------------------------|-------------|------------------|
| **SILAC forward** |                          |          |                          |             |                  |
| P53634           | Dipептидил peptidase 1 (CTSC) | 6        | 3.5849                   | 51,854      | 15-20            |
| Q9Y4W6           | AFG3-like protein 2 (AFG3L2) | 2        | 2.7856                   | 88,584      | 15-20            |
| Q57B44           | CAAX prenyl protease 1 homolog (ZMPSTE24) | 2        | 100                     | 54,813      | 15-20            |
| Q5VTE0           | Putative elongation factor 1-alpha-like 3 (EEF1A1PS) | 2        | 1.7272                   | 50,185      | 15-20            |
| P63261           | Actin, cytoplasmic 2 (ACTG1) | 2        | 5.4425                   | 41,793      | 5-10             |
| Q9S979           | Reticulin-3 (RTN3) | 2        | 2.3429                   | 112,611     | 15-20            |
| Q9NQC3           | Reticulin-4 (RTN4) | 1        | 100                     | 129,931     | 15-20            |
| Q929D4           | Zinc transporter SLC39A7 (SLC39A7) | 1        | 11.5738                  | 50,118      | 15-20            |
| P07666           | Beta-hexosaminidase subunit beta (HEXB) | 1        | 2.9101                   | 63,111      | 15-20            |
| Q16891           | Mitochondrial inner membrane protein (IMMT) | 1        | 100                     | 83,678      | 15-20            |
| Q86UE4           | Protein LYRIC (MTDH) | 1        | 100                     | 63,837      | 5-10             |
| Q8IB41           | Ras and EF-hand-domain-containing protein (RASEF) | 1        | 23.1859                  | 82,879      | 5-10             |
| Q05141           | ADP/ATP translocase 2 (SLC25A5) | 1        | 45.9929                  | 32,852      | 5-10             |
| Q8N8V7           | Olfactory receptor 5H2 (OR5H2) | 1        | 1.01                     | 35,974      | 5-10             |
| P07602           | Proactivator polypeptide (PSAP) | 1        | 3.1506                   | 58,133      | 5-10             |
| P07339           | Cathepsin D (CTSD) | 1        | 2.8517                   | 44,552      | 5-10             |
| **SILAC reverse** |                          |          |                          |             |                  |
| P53634           | Dipептидил peptidase 1 (CTSC) | 4        | 8.096                    | 51,854      | 15-20            |
| Q9NX40           | OCIA domain-containing protein-1 (OCIA1) | 3        | 100                     | 27,626      | 5-10             |
| P63261           | Actin, cytoplasmic 2 (ACTG1) | 3        | 21.9962                  | 41,793      | 5-10             |
| Q8N8V7           | Olfactory receptor 5H2 (OR5H2) | 2        | 23.1859                  | 82,879      | 5-10             |
| P12236           | ADP/ATP translocase 3 (SLC25A6) | 2        | 100                     | 32,866      | 5-10             |
| Q8IB41           | Ras and EF-hand-domain-containing protein (RASEF) | 1        | 1.9371                   | 82,879      | 25-30            |
| Q9BQ3E           | Tubulin alpha-1C chain (TUBA1C) | 1        | 100                     | 49,895      | 5-10             |
| Q9POL0           | Vesicle-associated membrane protein-associated protein A (VAPA) | 1        | 100                     | 27,893      | 5-10             |
| Q9Y230           | RuvB-like 2 (RUVBL2) | 1        | 100                     | 51,157      | 5-10             |
| Q86UE4           | Protein LYRIC (MTDH) | 1        | 100                     | 63,837      | 5-10             |
| P07602           | Proactivator polypeptide (PSAP) | 1        | 18.9825                  | 58,113      | 5-10             |

Protein fragments identified in both SILAC experiments were highlighted in bold.

aAccession number, gene name and molecular weight (MW) according to Uniprot database.

bNumber of Unique Peptide (C.I. 95%).
responses tended to be, however, higher at the same times (Figs. 2 and 3). The cumulative responses (magnitude), as calculated by the means, in all patients tested, of the frequencies of CD8+ and CD4+ Teff cells promptly producing IFN-γ, TNF-α, or both, in response to each single peptide pools, were always higher at both T1 and T2 than at T0, as well as at T2 as compared with T1 (Fig. 4). Notably, both the magnitude and the means of several CD8+ or CD4+ Teff cell responses against the single NM-neoAg peptide pools were higher in the subset of naive patients showing earlier stage tumor and who did not experience any neo-adjunctive chemotherapy before surgery, as compared with HDs (Fig. 4; Supplementary Fig. 6). The antigen-specific responses were confirmed by dose–curve analyses, supporting that they recognized antigens with remarkable T cell receptor avidity (Supplementary Fig. 6). The antigen-specific Teff cells, to produce high IFN-γ or TNF-α, or both, in response to the single peptides, at the T1 (after the chemotherapy protocol including CDDP) and T2 (after the subsequent nivolumab treatment). The resulting fold change (calculated as the ratio between percentage of responders among chemotherapy/nivolumab-treated patients, and the percentage of responders among chemotherapy-treated patients) clearly showed that the multi-specific responses were more strongly represented upon nivolumab treatment (Supplementary Figs. 8 and 9). Both CD8+ and CD4+ Teff cells from randomly selected patients studied rapidly degranulated, in terms of CD107a (a lysosomal-associated membrane protein-1) mobilization, in response to selected peptide pools derived from NM-neoAgs, whereas those isolated from HDs were virtually unable to perform these functions ex vivo (Supplementary Fig. 10). These effector responses were evident only upon the treatment with either the chemotherapy-alone or the consecutive nivolumab treatment. In addition, overlapping peptides derived from some random selected proteins (tubulin β-4b chain, heterogeneous nuclear ribonucleoprotein A1, glyceraldehyde-3 phosphate dehydrogenase) that were shown to be downregulated in CDDP-ap NSCLC cells, and upregulated in their live cell counterparts in the form of entire proteins, were also tested (Supplementary Fig. 11a); no significant CD8+ or CD4+ T cell responses against these peptides were shown in six patients analyzed, as compared with HDs (Supplementary Fig. 11b–e). Additional controls showed that the CD8+ or CD4+ Teff cell responses against multiple peptides derived from a known lung antigen, such as NY-ESO-156,57, increased upon chemotherapy, and even more upon nivolumab treatments in the peripheral blood of some patients tested, supporting the possibility that also conventional tumor antigens can be unveiled by chemotherapy (Supplementary Fig. 12).

Caspase cleavage improves cross-presentation of NM-neoAgs. To evaluate whether caspases have a role in preparing apoptotic tumor cell substrate for subsequent processing and presentation by APCs, we generated CD8+ T cell lines specific to pools containing epitopes (pool 1 and pool 2) related to NM-neoAgs, and tested them for their capacity to form IFN-γ spots (in an enzyme-linked immunospot [ELISPOT] assay) within 4–6 h of contact with autologous monocytes (as APCs) that had been pulsed with: the relevant peptide pools, CDDP-ap NSCLC cells alone, CDDP-ap NSCLC cells previously treated with a selective caspase-8 inhibitor (C8I), CDDP-ap NSCLC cells previously treated with a negative caspase control (K), or lysed NSCLC cells. Both the NM-neoAg-specific CD8+ T cell lines responded to both the direct presentation of the relevant peptide pools and the cross-presentation of CDDP-ap NSCLC cells by APCs, rather than the cross-presentation of lysed NSCLC cells (representing the proteome of live tumor cells) (Fig. 5). The treatment of CDDP-ap NSCLC cells with C8I (but not with K) blocked the cross-presentation (Fig. 5), validating the hypothesis that chemotherapy unveiled the related neoAgs by caspase cleavage in apoptotic cells. APCs that were simultaneously pulsed with C8I-treated apoptotic tumor cells and peptide pools preserved the capacity to present the latter, thus ruling out the possibility that apoptotic cells or C8I could affect the stimulatory capacities of APCs.

Correlation of NM-neoAg-specific T cells with overall survival and PD-1 decrease. The association between the level of functional Teff cell frequency and overall survival was studied in 12 patients, who experienced the combination of chemotherapy and immunotherapy protocol, and was computed through the log-rank (Mantel–Cox) test (Fig. 6). This analysis showed that patients’ survival was correlated with the capacity of CD8+ Teff cells, but not CD4+ Teff cells, to produce high IFN-γ or TNF-α levels in response to NM-neoAgs (one standard deviation above the average) at T2 (following the nivolumab treatment) (Fig. 6).
but not at T1 (after the chemotherapy protocol including CDDP).

No correlation was shown between overall survival and either the number of chemotherapy or nivolumab cycles received by the single patients, or the surgery treatment previously performed in 4 out of the 12 patients, who would be submitted to the chemotherapy/immunotherapy protocol. Interestingly, the follow-up study showed that the PD-1\(^{+}\) cells within both the NM-neoAg-specific CD4 and CD8 Teff cells increased upon chemotherapy (T1), but then they drastically decreased upon the nivolumab therapy (T2), coming back at the start values (Fig. 7). Notably, the decrease of the PD-1\(^{+}\) cell percentage at T2 paralleled the progressive increase of the total CD4\(^{+}\) and CD8\(^{+}\) Teff cells specific to NM-neoAgs (Fig. 7).

**Discussion**

In this study, we identified immunogenic neoAgs generated in chemotherapy-induced apoptotic tumor cells, by combining the SILAC-based MS technology quantitatively comparing the proteome of primary CDDP-ap and live NSCLC cells, and the “T cell interrogation system,” by which memory T cells longitudinally obtained from patients with late NSCLC stage, who would be submitted to CDDP and nivolumab, were used as a probe to recognize immunogenic NM-neoAgs\(^{38}\). By this multitask approach, we provided evidences showing that NM-neoAg-specific Teff cell responses increased upon chemotherapy, even more they were boosted by the nivolumab therapy, and correlated with both patients’ survival and decrease of PD-1 expression.

Our data support the hypothesis that chemotherapy-induced apoptosis of tumor cells plays a pivotal role in unveiling immunogenic NM-neoAgs\(^{38}\). By this multitask approach, we provided evidences showing that NM-neoAg-specific Teff cell responses increased upon chemotherapy, even more they were boosted by the nivolumab therapy, and correlated with both patients’ survival and decrease of PD-1 expression.
respond to peptides derived from entire proteins resulted upregulated in live tumor cells; activation of CD8\(^+\) T cell lines specific to NM-neoAgs was obtained upon cross-presentation of apoptotic tumor cells (expressing the appropriate fragmented antigens), rather than cross-presentation of lysed tumor cells (representing the proteome of live tumor cells), and was drastically reduced by treatment of APCs with caspase inhibitors in vitro. These observations support the definition of tumor-associated NM-neoAgs as caspase-cleaved fragments that are targeted to the processing machinery and cross-presented by APCs more efficiently than their entire protein counterparts in a consistent number of patients tested, in analogy with what happens in the case of (unfolded) DRiPs as compared with the standard (folded) proteins\(^3\). In this context, the wide presence of effector T cell responses against these apoptosis-related fragmented proteins (as detected by ex vivo assays) in the peripheral blood from several patients upon chemotherapy suggests that these T cells, to promptly respond ex vivo, had to recently encounter the corresponding antigens in vivo, supporting the quality of these tumor-associated fragmented proteins as public immunogenic NM-neoAgs.

It is interesting to point out that the totality of the immunogenic NM-neoAgs identified were overrepresented in CDDP-ap NSCLC cells as fragmented proteins, as compared with live NSCLC cells. This finding suggests that these self-Ags are tolerated when expressed by live cells in their complete form, but they would lose the self-identity acquiring that of NM-neoAgs, upon apoptosis generating caspase-cleaved fragmented proteins potentially more susceptible to processing and cross-presentation by APCs. We cannot exclude that other fragmented proteins can be generated in apoptotic cells by caspase cleavage that are at subthreshold level for the identification by our SILAC-based MS approach, or that diverse post-translational pathways can generate additional neoAgs.

Both NM-neoAg-specific CD8\(^+\) and CD4\(^+\) T eff cells displayed a wide range of functions including production of IFN-\(\gamma\) and/or TNF-\(\alpha\), as well as killing activity in response to the relevant epitopes ex vivo. However, the findings that CD8\(^+\) T eff cell responses...
tended to be wider than the CD4+ Teff responses in patients, and that only the former correlated with the overall survival suggests that CD8+ Teff cells provide the principal protective responses against tumors. On the other hand, we cannot rule out that CD4+ Teff cells can potentially contribute to mediate tumor regression.60–62 In this context, it is not surprising that some CD4+ Teff cells tested displayed the capacity to degranulate in response to NM-neoAgs, since cytotoxic CD4+ T cells have been demonstrated to contribute to immunopathology in various forms of pathologic conditions, including cancer.60,63

Importantly, NM-neoAgs derived from CDDP-ap tumor cells were recognized by memory T cells across several HLA-unrelated patients ex vivo, which in turn correlated with the patients’ survival. These data suggest that the resulting anti-tumor protection is likely due to the bystander effect of the wide storm of inflammatory cytokines produced by Teff cells in response to cross-presentation of apoptotic tumor cells by tissue-resident APCs, rather than by the direct killing of tumor cells, requiring an MHC-restricted antigen recognition on intact cells. In addition, these Teff cells may provide bystander (indirect) killing of neighboring live tumor cells in a non-antigen-specific manner.64 Therefore, our system would result advantageous for the identification of public immunogenic tumor NM-neoAg epitopes recognized by multiple HLA-mismatched patients. Consistent
with this possibility, recent evidences showed that necroptotic tumor cells confer tumor control across multiple syngeneic tumor models. Although chronic inflammation can promote initial carcinogenesis by the production of several inflammatory cytokines, including IFN-γ, TNF-α, interleukin-6 (IL-6), and IL-1, in combination with the production of reactive oxygen or nitrogen species by activated myeloid cells, the same pro-inflammatory cytokines released by immune cells in an ICD milieu can favor immune activation rather than suppression in the tumor microenvironment, and enable ultimately the immune response.

**Fig. 6** Kaplan–Meier survival curves. a, b Each Kaplan–Meier plot presents NSCLC patients, who experienced the combination of chemotherapy and nivolumab therapy (i.e., studied at T2). In two groups: “high IFN-γ (a) or TNF-α (b)” (blue) with above-average (median value) values of IFN-γ or TNF-α production in response to NM-neoAgs by CD8+ T cells among all samples, while “low IFN-γ (a) or TNF-α (b)” (gray) with values below average. Decreased number of live patients in a time point of 10 years is reported below the curves. *p < 0.05 by log-rank (Mantel–Cox) test.

**Fig. 7** ICB therapy boosts NM-neoAg-specific CD4+ and CD8+ T effector (Teff) cell responses in relation with a drastic reduction of PD-1 expression. a, b Representative FC (contour plot) analysis of PD-1 expression within the total gated CD8+ (a) or CD4+ (b) T cells producing IFN-γ, TNF-α, and both (sum of antigen-specific CD8+ or CD4+ T cells) to peptide pool 1, 3, or 4. FC analyses were performed in PBMCs obtained in T0 (before any treatment), T1 (after the chemotherapy treatment), or T2 (after the nivolumab treatment). c, d Each symbol in the left graphs represents the mean of percentage of CD8+ (c) or CD4+ (d) Teff cells producing IFN-γ, TNF-α, or both in response to a single peptide pool (of 12 pools) here defined as specific CD8+ or CD4+ T cells, whereas each symbol in the right graphs represents the mean of percentage of PD-1+ cells within the specific CD8+ (e) or CD4+ (d) Teff cells. The FC analyses were performed in PBMCs obtained from 14 NSCLC patients before any treatment (T0 N = 14), and from 11 patients after the nivolumab therapy (T2). Bars were showed as box and whisker graphs; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by two-way ANOVA with Tukey’s multiple comparison test.
system to act effectively against metastatic tumors. On this basis, the beneficial effects by checkpoint inhibitors depend on the presence of a pro-inflammatory "hot" environment.

The finding that naive patients, who were not submitted to neo-adjuvant chemotherapy and whose blood sample was obtained the day before surgery, showed detectable frequencies of NM-neoAg-specific T effector cells, made apoptotic by the natural T cell pressure against HDs, leads to the hypothesis that these responses were primed by NM-neoAg-specific T cells for unleashing the anti-tumor responses by the combination of chemotherapy and ICB or by vaccination.

The finding that these pre-existing memory T cells were almost undetectable at T0 (before chemotherapy and nivolumab treatments) in our advanced tumor patients supports the idea that they inevitably decrease in these patients, as a result of T cell exhaustion or by chemotherapeutic stimulation. Our data indicate that they can be reinvigorated following the double chemotherapy effect (i.e., increasing tumor cell apoptosis generating high levels of NM-neoAgs, and ICD induction), providing the appropriate signals (1, 2, 3, etc.) for the boosting of T cell expansion following checkpoint inhibitors, which ultimately correlates with overall survival. Whether other ICD forms, including necroptosis (occurring downstream of the receptor-interacting protein kinases RIPK1 and RIPK3), can enable tumor cells to generate similar or overlapping sets of NM-neoAg repertoire that may contribute to potentiate anti-tumor immunity is a crucial issue to investigate.

The observation that the percentage of NM-neoAg-specific CD4+ and CD8+ T cells expressing PD-1 increased upon chemotherapy indicates that NM-neoAgs, generated by chemotherapy-dependent apoptosis, principally activate and expand PD-1+ tumor-specific CD4+ and CD8+ T cells, providing thus the substrate on which anti-PD-1 therapy can perform its boosting effect directed towards the PD-1+ tumor-specific cell population. This hypothesis is supported by the evidence showing that the ICB therapy induced a further increase of the frequency of NM-neoAg-specific CD4+ and CD8+ T effector cells that paralleled a drastic reduction of PD-1 expression and correlated with the overall survival. Consistent with this finding, PD-1 blockade has been proposed to induce a pattern of metabolic and effector T cell-specific changes that was related with an enhancement of effector molecules (e.g., IFN-γ and granzymes) and in a decrease of the exhaustion markers TIM-3 and LAG-3. In addition, it has been recently demonstrated that PD-1 blockade counteracts the increase of PD-1 high CD4+ T follicular helper cells that accumulate at the tumor site and inhibits T effector functions in experimental tumor models.

Although the follow-up study of a larger cohort of patients is required to validate the association of patients’ survival with CD8+ T cell responses to the fragmented proteins identified in apoptotic tumor cells, an important facet of our study is that memory T cells targeting shared NM-neoAgs among several NSCLC patients can be detected in the peripheral blood, and can potentially be used for developing T cell-based immunotherapy across multiple cancer patients.

Methods

Study population. Human studies were performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and approved by the Institutional Ethical Committee (No. 2926). Informed consent was obtained from all patients. Histological diagnosis was determined based on microscopic features of carcinoma cells. We enrolled and monitored 14 stage IV NSCLC patients (10 LUAD and 4 LUSC): all patients were studied before and after various cycles of a chemotherapy protocol (including CDDP), whereas 12 (8 LUAD and 4 LUSC) of them were also studied after a subsequent treatment with several cycles with nivolumab (Table 2), by analyzing longitudinally memory T cell responses to several peptide pools derived from proteins that had been previously identified as fragmentated, or entire proteins in primary CDDP-ap or live NSCLC line by SILAC-based MS. CD8+ T cells were characterized within the first month after diagnosis in all enrolled patients. Nivolumab treatment started after failure (demonstrated by instrumental and/or biochemical metastatic progression) of CDDP chemotherapy. Demographic, clinical, and therapeutic characteristics of these NSCLC patients are described in Supplementary Table 1. Possible EGFR and KRAS mutations were detected by Real-Time PCR (Applied Biosystems 7500, USA). Two out of the 14 patients could not be submitted to nivolumab after CDDP therapy, because one of them showed an ALK translocation and underwent oral Crizotinib target therapy, while the other patient spontaneously left our Oncology Center (Sapienza Universita of Rome). As a control, T cell responses were also studied in PBMCs from seven patients with stage IV NSCLC (four with H1A, one with H1B, one with I1A, and one with I1A), who did not require neo-adjuvant chemotherapy, and whose blood sample was obtained immediately before (1 day) the surgery resection (naive patients) (Supplementary Table 1), and in PBMCs from 10 HDs.

Isolation and characterization of NSCLC cells. The NSCLC cell line named EptTLLu was established in the Immunology and Immunotherapy Unit of Regina Elena National Cancer Institute, Rome, and obtained from surgery specimen of a male patient who underwent right upper lobectomy. Possible EGFR and KRAS mutations were detected in both tissue biopsy and tumor cell line by Real-Time PCR (Applied Biosystems 7500, USA) using TaqMan (CE-IVD EntroGen Kit). The patient did not receive postoperative chemotherapy or radiation therapy. Tissue was detected in both tissue biopsy and tumor cell line by Real-Time PCR (Applied Biosystems 7500, USA) using TaqMan (CE-IVD EntroGen Kit). The patient did not receive postoperative chemotherapy or radiation therapy.

Informed consent was obtained from patients. The present study was approved by the ethics committee of the Regina Elena National Cancer Institute in Rome (CEC/722/14). Fresh tumor tissue (within 1 h after surgical removal) was washed in phosphate-buffered saline (PBS, Corning, USA) and minced into small pieces <1 mm² using a scalpel. The specimen was enzymatically digested by trypsin (Sigma-Aldrich, USA) at a final concentration of 0.25 M for 30 min at 37 °C in a humidified incubator with 5% of CO2. Then, RPMI-1640 with 10% of fetal bovine serum (FBS, Gibco, USA) was added, and after washing, cells were transferred into a standard tissue culture plate and cultured in RPMI-1640 with penicillin/streptomycin supplemented with 10% FBS and glutamine (Sigma-Aldrich). The cultures were maintained at 37 °C in a humidified incubator with 5% of CO2. The culture medium was changed every 2–3 days. Cells were passaged after detachment when the cells reached 80–90% confluence. All the studies were performed with the initial five passages. Cell lines of epithelial origin were checked by FC staining of epithelial cell surface antigen CD326 (Ep-CAM) (Miltenyi Biotec, Germany) (Supplementary Fig. 1a), as well as when cell morphology was also consistent with the epithelial origin (Supplementary Fig. 1b). The cell lines were analyzed for 24 generic markers using the PowerPlex Fusion System Kit (BMR Genomics s.r.l., Italy).

CDDP-dependent apoptosis of NSCLC cells. Primary NSCLC cell lines were plated (1.5 × 10^6 cells/well) in 6-well plates and grown overnight. Cells were treated on the following day with 2-fold serial dilution of CDDP (from 1.25 to 0.078 μM) of NSCLC cells were detected by the Annexin V/Fixable Viability Dye (eBioscience, USA) and anti-active-caspase-3 (BD Biosciences, USA) staining. Each treatment was in duplicate and three different experiments were performed. After 72 h, cells were harvested, transferred into flow tubes, pelleted, re-suspended in 100 μL of fresh 1× Fixable Viability Dye eFluor780 in PBS and incubated for 30 min at room temperature. Cells were then washed and re-suspended in 100 μL of AnnexinV binding buffer plus Annexin V fluorescein isothiocyanate (FITC) for 15 min at room temperature. Cells were fixed and permeabilized with Cytofix/Cytoperm Kit (BD Biosciences) and stained with Brilliant Violet 420 anti-active-caspase-3 for 20 min at 4 °C. After washing, samples were acquired by FC within 1 h using an LSRFortessa (BD Biosciences). Experiments were analyzed using the Flowjo software (TreeStar Inc., version 10.1r5) (Supplementary Fig. 1).

SILAC labeling of primary NSCLC cells and sorting. Primary NSCLC cells were grown in either SILAC heavy ([13C615N4-arginine and 13C6-lysine)] or SILAC light ([14C615N4-arginine and 14C6-lysine)] conditions for eight passages before the first experiment. This period lasted about 3 weeks, until the SILAC heavy cells labeling was complete (SILAC LC Protein Quantitation Kit, cod. A8660, Thermo Fisher Scientific, USA). To analyze a reverse duplicate, NSCLC cells were also grown in SILAC light or SILAC heavy media, under the same experimental conditions. Total metabolic incorporations were verified by MS. Then, cultured NSCLC cells that were metabolically labeled with heavy isotope (from SILAC heavy) were induced to apoptosis by 0.625 μM CDDP (Thermo Fisher Scientific, USA). CDDP treated-apoptotic and live cells for protein identification, NSCLC cells, grown in heavy and light SILAC media, were labeled with Annexin V FITC/Fixable

ARTICLE

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0811-x | www.nature.com/commsbio

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0811-x | www.nature.com/commsbio

COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0811-x | www.nature.com/commsbio
Viability Dye eFluor780 as previously described. Sorting was performed using a FACSAria III (BD Biosciences) equipped with 488, 561 and 633 nm laser and the FACSDiva software version 6.1.3: BD Biosciences. The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE25 partner repository with the dataset identifier PXD016997.

IHC analysis. IHC analysis was performed on serial, formalin-fixed paraffin-embedded or hematoxylin–eosin-stained sections of cancer tissue samples from five NSCLC patients, who were submitted to neo-adjuvant (CDDP) therapy before surgery resection. Antibodies used were: anti-PSAP (Abcam, Cambridge, UK), anti-LYRIC/AEGI (Abcam, Cambridge, UK) and anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, MA) (Supplementary Table 2). The immunoreactions were revealed by Bond Polymer Refine Detection (Leica Biosystem, Milan, Italy) on an automated autostainer in the order Max, Leica). The HLA restriction of the different proteins was performed independently by two investigators blinded to clinical data. Apoptotic cells and apoptotic bodies were characterized in hematoxylin–eosin-stained sections by cell shrinkage, with condensed hyperchromatic nuclear chromatin and deeply eosinophilic cytoplasm, and dense extra- or intracellular chromatin fragments, with or without associated cytoplasm, respectively. They were visualized by activated caspase-3 staining in formalin-fixed paraffin-embedded sections.

Synthetic overlapping peptides. Eight fragmented proteins (upregulated in CDDP-AP NSCLC cells) and three entire proteins (upregulated in live NSCLC cells) were selected for immunologic validation and analyzed for their amino acid sequence (Supplementary Figs. 4a and 11a). For each of the 20 residues before and after MS-identified sequence was selected. For custom synthesis (Mimotopes Peptide Company, Australia), 37 20-mer peptides with an overlapping region of 12 amino acids (derived from the eight fragmented proteins), as well as 22 20-mer peptides with an overlapping region of 12 amino acids (derived from the three entire proteins), were designed (Supplementary Table 2). The six to seven peptides were pooled in order that each single peptide was shared between two pools according to the matrix scheme in Supplementary Fig. 4a, b. As a control, multiple overlapping NY-ESO-1 peptides (PepFivator NY-ESO-1 premium grade, human, Mileniy Biotech) were used.

Antigen-specific T cell assays and flow cytometry analyses. PBMCs were isolated from fresh heparinized blood by density gradient centrifugation with lymphocyte (Cedarlane, Canada), and collected in complete RPMI medium containing 10% heat-inactivated FBS (HyClone GE Healthcare Life Sciences, USA), 2 mM l-glutamine (Sigma-Aldrich), penicillin/streptomycin (EuroClone, Italy), non-essential amino acids (EuroClone), and sodium pyruvate (EuroClone). Cells were stimulated or not with 20 μg/ml peptide pool plus 1 μg/ml of anti-CD28 mAb (BD Biosciences) and the Protein Transport Inhibitor Cocktail (brefeldin A and monensin, eBioscience) for 5 h. After stimulation, cells were fixed and permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) at 4 °C for 20 min, washed, and stained with mAbs to CD4, CD8, CC57, CD45RA, PD-1 and with a cocktail of labeled mAbs to CD14, CD16, CD56, CD19 (dump channel was included for the exclusion of monocytes, natural killer cells, and B cells, respectively; antibody details are reported in Supplementary Table 2) for 20 min at 4 °C in PBS containing 2% FBS. To analyze cytokine production, cells were fixed and permeabilized using the BD Cytometric Bead Array Kit (BD Biosciences). For intracellular cytokine staining, cells were stimulated for 18 h at 37 °C. After antigen stimulation, cells were washed and stained with Fixable Viability Dye eFluor780 (eBioScience) for the exclusion of dead cells in PBS and then incubated for 30 min at room temperature. The cells were cooled to 4 °C, washed and resuspended in PBS containing 5% FCS and 1% sodium azide before analysis.

Isolation and expansion of CD8+ T cell lines. Highly purified CD8+ T cells and monocytes were isolated from a patient’s PBMCs responding to the peptide pools 1 and 2, by magnetic bead separation with the CD8+ T Cell Isolation Kit and Pan Monocyte Isolation Kit (Mileniy Biotech), respectively. Antigen-specific CD8+ T cell lines were obtained upon repeated (bi-weekly) stimulation with autologous irradiated PBMCs that were previously pulsed with the relevant peptide pools and expanded in IL-2-conditioned medium, as previously described.

Cross-presentation assay. Fresh NSCLC cells (10 × 106) were cultured in the presence or absence of 14 μg/ml C11 (ZIETD-FMK) or a negative caspase control (Z, K-FA-FMK) (BD Biosciences) for 1 h at 37 °C. Then, they were induced to undergo apoptosis by CDDP treatment and processed for analysis, as
described above. Control cells were represented by live NSCLC cells, which were promptly lysed by repeated freezing and thawing. Highly purified monocytes (3 × 10⁵) were treated with increasing concentrations of CII-treated, Ktreated, untreated apoptotic NSCLC cells, control lysed cells, or peptides in U-bottom 96-well plates for 18 h. Then, APCs were cultured with ligned antigen-specific CD8+ T cells (2–3 × 10⁶) and IFN-γ spot formation by CD8+ T cells was promptly revealed after 6–8 h at 37°C by an ELISPOT assay, as previously described. Each pool was tested in triplicate. The HLA restriction of these responses was demonstrated by blocking responses with an appropriate anti-class I mAb.

Bioinformatic analysis of SILAC experiment. The over-representation analysis of down- and upregulated proteins obtained from SILAC analysis was performed online with PANTHER classification system (version 14.1 – 2018_04 release; http://www.pantherdb.org). GO analysis within biological process category (cellular process [level 2] and sub-categories) was evaluated. In particular, enriched genes for “apoptotic mitochondrial changes – GO:0006837” in mitochondrion organization category, “response to toxic substance GO:0009636,” and “response to drug GO:0042693” in response to chemical category were reported only in upregulated proteins (Supplementary Fig. 2b).

Statistics and reproducibility. Statistical analyses were performed using the software GraphPad Prism version 6.0b. To compare cytokine production in response to each single peptide pool among HD, NP, T0, T1, and T2, unpaired Student’s t test was used. To compare the overall cytokine production in response to all pools among HD, T0, T1, and T2, one-way analysis of variance (ANOVA) test with Tukey’s multiple comparison test was used. PD-1 expression analysis was performed with two-way ANOVA test. Cross-presentation and dose–response curve analyses were performed with unpaired Student’s t test. Kaplan–Meier survival curve with log-rank (Mantel–Cox) test was performed to compare two groups of patients selected by a median cut-off. All statistical analyses were performed using the statistical software R version 3.3.0.

Received: 14 August 2019; Accepted: 6 February 2020; Published online: 25 February 2020.

References
1. Herbst, R. S., Morgenstern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. Nature 553, 446–454 (2018).
2. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
3. Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
4. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
5. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
6. Okazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S. & Honjo, T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14, 1212–1218 (2013).
7. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
8. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2453–2465 (2012).
9. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
10. Gilboa, E. The makings of a tumor rejection antigen. Immunity 11, 263–270 (1999).
11. Armistead, T. M. Cellular therapy against public neoantigens. J. Clin. Invest. 129, 506–508 (2019).
12. Cafi, G. et al. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat. Commun. 10, 449 (2019).
13. Gubin, M. M., Artyomov, M. N., Mardis, E. R. & Schreiber, R. D. Tumor neoantigenics building a framework for personalized cancer immunotherapy. J. Clin. Invest. 125, 3413–3421 (2015).
14. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
15. Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019).
16. Kneksted, P. et al. Neoantigen-activated T cells exhibit broad TPS5 mutant immunogenicity in patients with epithelial cancers. J. Clin. Invest. 129, 1109–1114 (2019).
17. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2019).
18. van der Lee, D. L. et al. Mutated nucleosomiphin 1 as immunotheraput target in acute myeloid leukaemia. J. Clin. Invest. 129, 774–785 (2019).
19. Milo, I. et al. The immune system profoundly restricts intratumor genetic heterogeneity. Sci. Immunol. 3, https://doi.org/10.1126/sciimmunol.aat1435 (2018).
20. Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125, 3981–3991 (2015).
21. Khodadoust, M. S. et al. Antigen presentation profiling identifies broad TPS5 mutant immunogenicity in patients with epithelial cancers. J. Clin. Investig. 125, 3981–3991 (2015).
22. Simonart, V. et al. Bystander CD4+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575–579 (2018).
23. Hanada, K., Yewdell, J. W. & Yang, J. C. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427, 252–256 (2004).
24. Coubald, M. et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci. Transl. Med. 5, 203ra125 (2013).
25. Malaker, S. A. et al. Identification of glycopeptides by posttranslationally modified neoantigens in leukemia. Cancer Immunol. Res. 5, 376–384 (2017).
26. Oliveira-Ferrer, L., Legler, K. & Milde-Langosch, K. Role of protein glycosylation in cancer metastasis. Semin. Cancer Biol. 44, 141–152 (2017).
27. Liepe, J. et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354, 354–358 (2016).
28. Brentville, V. A. et al. Citrullinated vimentin presented on MHC-II in human cells is a target for CD4+ T cell-mediated antitumor immunity. Cancer Res. 76, 548–560 (2016).
29. Marijt, K. A. et al. Identification of non-mutated neoantigens presented by cancer patients. J. Exp. Med. 215, 1235–1237 (2018).
30. Yewdell, J. W. & Nicchitta, C. V. The DRP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27, 368–373 (2006).
31. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
32. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
33. Kepp, O. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 3, 695861 (2014).
34. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
35. Casciola-Rosen, L. A., Anhalt, G. & Rosen, A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179, 1317–1330 (1994).
36. Rawson, P. M. et al. Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat. Med. 13, 1431–1439 (2007).
37. Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691–1701 (2005).
38. Chang, C. L. et al. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res. 73, 119–127 (2013).
39. Lysterhus, W. J. et al. Platinum-based drugs disrupt STAA-mediated suppression of immune responses against cancer in humans and mice. J. Clin. Investig. 121, 3100–3108 (2011).
40. Galpaya, E. et al. Tumor-specific cytokine production contributes to the antitumor immune response. Cancer Res. 73, 119–127 (2013).
41. Parodi, M. et al. Discovery of chemotheraphy-associated ovarian cancer antigens by interrogating memory T cells. Int. J. Cancer 134, 1823–1834 (2014).
42. Cammarata, I. et al. Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis. J. Autoimmun. 99, 81–97 (2019).
